(2S,3R)-4-(tert-butoxycarbonyl(methyl)amino)-3-(tert-butyldimethylsilyloxy)-2-methylbutanoic acid | 1255212-71-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2S,3R)-4-(tert-butoxycarbonyl(methyl)amino)-3-(tert-butyldimethylsilyloxy)-2-methylbutanoic acid
• 英文别名: 4-(tert-butoxycarbonyl(methyl)amino)-3-(tert-butyldimethylsilyloxy)-2-methylbutanoic acid；(2S,3R)-3-[tert-butyl(dimethyl)silyl]oxy-2-methyl-4-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoic acid
• CAS: 1255212-71-5
• 化学式: C₁₇H₃₅NO₅Si
• 分子量: 361.554
• InChiKey: XOHGHZGFWBWPQH-STQMWFEESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.96
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S,3R)-4-(tert-butoxycarbonyl(methyl)amino)-3-(tert-butyldimethylsilyloxy)-2-methylbutanoic acid 在 palladium on activated charcoal dimethyl sulfide borane 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 氢气 、 三乙胺 、 N,N-二异丙基乙胺 、 cesium fluoride 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 40.0h， 生成 tert-butyl (((2R,3R)-10-amino-5-((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-3-methyl-6-oxo-3,4,5,6-tetrahydro-2H-benzo[b][1,5]oxazocin-2-yl)methyl)(methyl)carbamate
  参考文献：
  名称：

  [EN] SMALL MOLECULE INHIBITORS FOR TREATING PARASITIC INFECTIONS
  [FR] INHIBITEURS À PETITES MOLÉCULES UTILISABLES EN VUE DU TRAITEMENT D'INFECTIONS PARASITAIRES

  摘要：

  本发明涉及公式I化合物或其药学上可接受的酯、盐、前药或代谢物。

  公开号：

  WO2012112568A1
• 作为产物：
  描述：

  2-(N-Boc-N-甲基氨基)乙醇 在 2,6-二甲基吡啶 、 草酰氯 、 双氧水 、 potassium carbonate 、 二甲基亚砜 、 三乙胺 、 sodium hydroxide 、 双环己基(三氟甲烷磺酰氧基)硼烷 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 叔丁醇 为溶剂， 反应 12.75h， 生成 (2S,3R)-4-(tert-butoxycarbonyl(methyl)amino)-3-(tert-butyldimethylsilyloxy)-2-methylbutanoic acid
  参考文献：
  名称：

  Practical asymmetric synthesis of β-hydroxy γ-amino acids via complimentary aldol reactions

  摘要：

  Orthogonally protected chiral beta-hydroxy-gamma-amino acids can be accessed in >100 g quantities from readily available starting materials and reagents in three to four steps. These chiral synthons contain two adjacent stereocenters along with suitably protected functional groups (O-TBS, N-Boc) for downstream reactivity. Implementation of two existing aldol technologies allows rapid access to all possible stereo-isomers of 1. The guiding principles during reaction optimization were reaction scalability and operational efficiency. Conversion of the amino acids to a variety of chiral building blocks in one to two steps demonstrates their synthetic utility. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2011.06.043

文献信息

• An Aldol-Based Build/Couple/Pair Strategy for the Synthesis of Medium- and Large-Sized Rings: Discovery of Macrocyclic Histone Deacetylase Inhibitors
  作者：Lisa A. Marcaurelle、Eamon Comer、Sivaraman Dandapani、Jeremy R. Duvall、Baudouin Gerard、Sarathy Kesavan、Maurice D. Lee、Haibo Liu、Jason T. Lowe、Jean-Charles Marie、Carol A. Mulrooney、Bhaumik A. Pandya、Ann Rowley、Troy D. Ryba、Byung-Chul Suh、Jingqiang Wei、Damian W. Young、Lakshmi B. Akella、Nathan T. Ross、Yan-Ling Zhang、Daniel M. Fass、Surya A. Reis、Wen-Ning Zhao、Stephen J. Haggarty、Michelle Palmer、Michael A. Foley

  DOI：10.1021/ja105119r

  日期：2010.12.1

  Despite some stereochemical dependencies, the ring-forming reactions were optimized to proceed with good to excellent yields, providing a variety of skeletons ranging in size from 8- to 14-membered rings. Scaffolds resulting from the RCM pairing reaction were diversified on the solid phase to yield a 14 400-membered library of macrolactams. Screening of this library led to the discovery of a novel class

  应用基于羟醛的构建/耦合/配对 (B/C/P) 策略来生成立体化学和骨架不同的小分子的集合。在构建阶段，进行了一系列不对称的合成和反羟醛反应以产生 Boc 保护的 γ-氨基酸的四种立体异构体。此外，还生成了 O-PMB 保护的丙氨醇的两种立体异构体，以提供手性胺偶联伙伴。在偶联步骤中，通过偶联手性酸和胺结构单元合成了八种立体异构酰胺。随后将酰胺还原以生成相应的仲胺。在配对相中，采用了三种不同的反应来实现分子内成环过程：亲核芳香取代 (S(N)Ar)、Huisgen [3+2] 环加成和闭环复分解 (RCM)。尽管存在一些立体化学依赖性，但对成环反应进行了优化，以从良好到极好的产率进行，提供了大小从 8 到 14 元环的各种骨架。由 RCM 配对反应产生的支架在固相上多样化，以产生 14 400 成员的大环内酰胺文库。对该文库的筛选导致发现了一类新的组蛋白去乙酰化酶抑制剂，其表现出混合酶抑制
• Diversity-Oriented Synthesis-Facilitated Medicinal Chemistry: Toward the Development of Novel Antimalarial Agents
  作者：Eamon Comer、Jennifer A. Beaudoin、Nobutaka Kato、Mark E. Fitzgerald、Richard W. Heidebrecht、Maurice duPont Lee、Daniela Masi、Marion Mercier、Carol Mulrooney、Giovanni Muncipinto、Ann Rowley、Keila Crespo-Llado、Adelfa E. Serrano、Amanda K. Lukens、Roger C. Wiegand、Dyann F. Wirth、Michelle A. Palmer、Michael A. Foley、Benito Munoz、Christina A. Scherer、Jeremy R. Duvall、Stuart L. Schreiber

  DOI：10.1021/jm500994n

  日期：2014.10.23

  Here, we describe medicinal chemistry that was accelerated by a diversity-oriented synthesis (DOS) pathway, and in vivo studies of our previously reported macrocyclic antimalarial agent that derived from the synthetic pathway. Structure-activity relationships that focused on both appendage and skeletal features yielded a nanomolar inhibitor of P. falciparum asexual blood-stage growth with improved solubility and microsomal stability and reduced hERG binding. The build/couple/pair (B/C/P) synthetic strategy, used in the preparation of the original screening library, facilitated medicinal chemistry optimization of the antimalarial lead.
• Practical asymmetric synthesis of β-hydroxy γ-amino acids via complimentary aldol reactions
  作者：Bhaumik A. Pandya、Sivaraman Dandapani、Jeremy R. Duvall、Ann Rowley、Carol A. Mulrooney、Troy Ryba、Michael Dombrowski、Marie Harton、Damian W. Young、Lisa A. Marcaurelle

  DOI：10.1016/j.tet.2011.06.043

  日期：2011.8

  Orthogonally protected chiral beta-hydroxy-gamma-amino acids can be accessed in >100 g quantities from readily available starting materials and reagents in three to four steps. These chiral synthons contain two adjacent stereocenters along with suitably protected functional groups (O-TBS, N-Boc) for downstream reactivity. Implementation of two existing aldol technologies allows rapid access to all possible stereo-isomers of 1. The guiding principles during reaction optimization were reaction scalability and operational efficiency. Conversion of the amino acids to a variety of chiral building blocks in one to two steps demonstrates their synthetic utility. (C) 2011 Elsevier Ltd. All rights reserved.
• [EN] SMALL MOLECULE INHIBITORS FOR TREATING PARASITIC INFECTIONS<br/>[FR] INHIBITEURS À PETITES MOLÉCULES UTILISABLES EN VUE DU TRAITEMENT D'INFECTIONS PARASITAIRES
  申请人：BROAD INST INC

  公开号：WO2012112568A1

  公开（公告）日：2012-08-23

  The invention relates to a compound of Formula I or a pharmaceutically acceptable ester, salt, prodrug or metabolite thereof;

  本发明涉及公式I化合物或其药学上可接受的酯、盐、前药或代谢物。